$VPRO SOLID DD ~~~~~ COMPANY & WEBSITE LINKS

New Post Public Reply Private Reply Replies (0) Message Board
MoneyMaker
$VPRO SOLID DD ~~~~~ COMPANY & WEBSITE LINKS ~~~~~~

VIROPRO INC.
http://www.viropro.net

SUBSIDIARY

Alpha Biologics
http://www.alphabiologics.com

~~~~~ 6 REASONS TO BUY ~~~~~~
New Top Rate Management >>
http://www.viropro.net/leadership-team/

Auditied Filings and Migration to New Stock Exchange NASDAQ/NYSE

Partnership Agreement worth Hundreds of Millions $$'s with Top Distributor

Share Structure is Amazing at 1.2 Billion with more than 50% Held by Institutions.

Float 39,000,000

Insiders Hold 48,000,000

Spring Hill Bioventures Sdn Bhd
340,000,000

THG Capital Sdn Bhd
184,000,000

Intas Biopharmaceuticals Ltd.
106,916,666

No Dilution No Toxic Debt


~~~~~LATEST NEWS OR FILINGS~~~~~~

Last 2 8-K's Speak Volumes about the Future of VIROPRO, Please read as they are full of Important Facts and really show the New Management Team is getting serious with respect to bringing Value to the Shareholders.

Shareholder Letter >> Current Report Filing (8-k)Edgar (US Regulatory) • Mon Jul 28,2014 8:45 AM

New Management Team >> Current Report Filing (8-k)Edgar (US Regulatory) • Fri Jun 13,2014 7:44 AM

525,000,000 Shares Held >> Amended Statement of Beneficial Ownership (sc 13d/a)Edgar (US Regulatory) • Tue Feb 25,2014 1:12 PM

Current Report Filing (8-k)Edgar (US Regulatory) • Fri Nov 8,2013 10:35 AM

Current Report Filing (8-k)Edgar (US Regulatory) • Thu Nov 7,2013 10:03 AM

~~~~~COMPANY WEBSITE INFO~~~~~~

Company Overview


Viropro is an integrated developer and manufacturer of biopharmaceutical products that address unmet medical need in an efficient and cost-effective way.

Operating primarily through its wholly-owned subsidiary Alpha Biologics, the company has a team of experts and a state-of-the-start production facility that can rapidly move from benchtop to bedside. 

We intend to develop our own products for commercial sale as well as make our facility available for contract manufacturing.  With access to a highly trained work force and low operating costs, Viropro should be your choice as a development partner for life-saving biotherapeutics.

Alpha Biologics houses a bio-manufacturing facility located in Penang, Malaysia built to US FDA and European EMEA current Good Manufacturing Practices (cGMP) standards. Our 5,000m2 plant located in the Penang Science Park was designed for the manufacture of biologics (including biosimilars) for pre-clinical and Phase I, II and III clinical trials and early stage commercial operations. Within the plant is state-of-the-art custom-made manufacturing equipment, including a 500L bioreactor capacity and room for expansion to commercial scale.

Services

The company’s principal objective is to provide high-yield development and GMP manufacturing services to biopharmaceutical companies in global markets with unmet medical needs.

With its state-of-the-art production facility at the crossroads of rapidly developing markets in Asia, Viropro is uniquely positioned provide rapid and cost-effective scale up for global pharmaceutical development. 

Alpha Biologics operates a 55,000 square foot facility located in the Penang Science Park, a short drive from the Penang International Airport.  Designed and built by industry experts to the exacting standards necessary for FDA and EMEA cGMP certifciation, the facility is ideally suited for scale-up and early commercial production of biosimilars, biobetters and novel drug delivery technologies.

Uniquely Compelling Advantages

Brand new state-of-the-art facility and equipment expressly designed to shorten production time and minimize costs Lower operational cost and service fees Facility pre-designed for expansion as needed Same equipment in PD and GMP areas – minimizes risk and tech transfer time No IP, platform technology, etc. complications Malaysia is a member of PIC/Opportunity for Halal certification of facility/processes

Investor Overview

Viropro is a publicly traded company currently listed on the OTC Pink under the ticker VPRO.

The company plans to become fully reporting in the near future and migrate to another stock exchange


~~~~~ CHARTS ~~~~~~

VPRO Daily Chart >>http://stockcharts.com/h-sc/ui?s=VPRO&p=D&b=5&g=5&id=p13283364476


VPRO Weekly Chart >> http://stockcharts.com/h-sc/ui?s=VPRO&p=W...1727910178

~~~~~ OTHER INFORMATION ~~~~~~

Portfolio Valuation

Viropro estimates the combined, aggregate realizable value of its biosimilars portfolio to be in the range of $33 million to $42 million, depending upon market dynamics of the individual products.

The products include biosimilar version of Avastin (bevacizumab), Erbitux (cetuximab), Herceptin (trastuzumab), Humira (adalimumab ), Rituxan (rituximab) and a non-disclosed biological used for cancer and immune-disease indications.

The biosimilars are generic versions of Humira, Rituxan, Avastin, Herceptin, Erbitux, and one other non-disclosed biotherapeutic. The companies project that Viropro commercial and manufacturing royalties have the potential to grow to an annual revenue rate of $60–$150 million in 10 years. The partnership plans to launch its first product by late 2014.

Huge Documents Involving Gilead, Celgene, Amgen, Biogene Idec and So Many Top Pharmaceuticals...VIROPRO is a Steal considering the Competitor's Value.... 73 Page Pharmaceutical & Biotechnology 2014 Outlook >> https://www.google.ca/url?sa=t&source=web...7CmJfnK8QA

Active SOS >> https://nvsos.gov/sosentitysearch/CorpDetails...amp;nt7=0j

Employees

The Company has 34 employees.  Two of the employees are Viropro’s senior executive officers and seven are employees of BPD.  Under Alpha Biologics, there are 20 employees in Penang, Malaysia and 5 in Cambridge, UK.

Competitors Capitalization

Lonza Group AG  (SWX:LONN)
$8 billion

Pharmaceutical Product Development, Inc. (Nasadaq PDI)
$5 billion

Cambrex Corporation (NYSE:CBM)
$682 Million

Bioanalytical Systems, Inc. (Nasdaq:BASI)
$20 Million

Viropro,Inc. (PINK :VPRO)
$9.5 million

VIROPRO INC. is the Absolute amazing Bio similar play. Which many of your top rate companies patents are expiring in 2017. Giving VPRO a huge head start on the future of Biosimilars which is expected to top $30 Billion by 2020.

5 PATENTS USES and 1 Undisclosed >>

Bevacizumab  (pronounced /bev-a-Sizz-uh-mab/,[1] trade name Avastin,Genentech/Roche) is an angiogenesis inhibitor, as a drug that slows the growth of new blood vessels. It is licensed to treat various cancers, including colorectal, lung, breast (outside the USA), glioblastoma (USA only), kidney and ovarian.

b]Cetuximab (Erbitux)[/b] is an epidermal growth factor receptor (EGFR) inhibitor used for the treatment of metastatic colorectal cancer, metastatic non-small cell lung cancer [1] andhead and neck cancer. Cetuximab is a chimeric (mouse/human) monoclonal antibody given by intravenous infusion that is manufactured and distributed in the United States by the drug companies Bristol-Myers Squibb and Eli Lilly and Company and in Europe by the drug company Merck KGaA.

Trastuzumab  (INN; trade names Herclon,Herceptin) is a monoclonal antibody that interferes with the HER2/neu receptor. Its main use is to treat certain breast cancers.

Adalimumab , trade name Humira, is a TNF inhibiting anti-inflammatory drug. AbbVie's trade name is derived from the acronym of "human monoclonal antibody in rheumatoid arthritis" (HUMIRA). Adalimumab binds totumor necrosis factor-alpha (TNFα), preventing it from activating TNF receptors; TNFα inactivation has proven to be important in downregulating the inflammatory reactions associated with autoimmune diseases. Adalimumab has been approved in the United States for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, moderate to severe chronic psoriasis and juvenile idiopathic arthritis.

Rituximab  (trade names Rituxan, MabTheraand Zytux) is a chimeric monoclonal antibodyagainst the protein CD20, which is primarily found on the surface of immune system B cells. Rituximab destroys B cells and is therefore used to treat diseases which are characterized by excessive numbers of B cells, overactive B cells, or dysfunctional B cells. This includes many lymphomas,leukemias, transplant rejection, andautoimmune disorders.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

GALC Launches Tender Offer on 2027 Notes Amid Debt Play

Updated Category News Views 70

Aviation Leasing Giant's Strategic Financial Move Well folks, we're staring down the barrel of a financial maneuver by Global Aircraft Leasing Co., Ltd. (GALC) that’s not just another day at the office. They've kicked off a cash tender offer for their 8.750% Senior Secured Notes due 2027, aiming to sweep up any and all outstanding ones. That's $932 million in principle...

Continue Reading
Cracking Life Insurance Needs: John Dorsa's Insights

Updated Category News Views 119

Life Insurance: A Necessary Puzzle Life’s uncertainties have a way of putting a wrench in our plans, and nothing screams uncertainty like figuring out life insurance. But fret not! HelloNation’s got insights on this financial maze, and they’ve roped in insurance pro John Dorsa from Ridgeland to help out. Calculating Coverage Needs Forget the one-size-fits-all...

Continue Reading
Choate's Expands to New Mid-South Markets

Updated Category News Views 155

Family Traditions Drive Choate's Growth Back in the day, you might've thought the family-run businesses were a dying breed, right? Not in the case of Choate's Air Conditioning, Heating, Plumbing & Electrical. These folks aren't just holding the fort; they're storming new territories across the Mid-South like they've got something to prove—or maybe just something to...

Continue Reading
Zettia R. Barnes: Charting a Path in Home Healthcare

Updated Category News Views 146

The Lifeline of Home Healthcare in DeSoto You know, it ain't every day that someone like Zettia R. Barnes steps up in the realm of home healthcare and makes a mark that genuinely sticks. From rubbing shoulders with patients to steering a whole dang organization like Angels of Hands Home Health Agency Corp., she's got her hands full—and frankly, it’s folks like her who...

Continue Reading
Texxon Faces Revenue Slide Amid Strategic Shifts

Updated Category News Views 108

Texxon's Strategic Transitions and Financial Headaches Texxon Holding Limited (NASDAQ:NPT) just laid their cards on the table, unveiling a mixed bag in their fiscal year 2026 results. As the world's chemical and plastics scene faces winds of change, Texxon buckled down and tried to steer the ship clear from the rocks. It's a balancing act juggling market headwinds, a new...

Continue Reading
Québecor Makes Its Move: Eye on TELUS Amid Telecom Shakeup

Updated Category News Views 142

The Offer That Shocked the Telecom Markets Just when you think you’ve figured out the lay of the land, someone throws a curveball. Québecor’s decision to take a run at TELUS is shaking up Canada’s telecom scene big time. This isn’t just another M&A whisper; it’s a roaring freight train of a proposal valued at a whopping $31 billion. And TELUS, not just sitting...

Continue Reading
Paris Baguette Expands U.S. Presence with New Georgia Café

Updated Category News Views 163

Café Culture Meets Expansion Chase You ever sip a cup of coffee and hear the rustle of opportunity in the steam? That's what's brewing at Paris Baguette with their new opening in Peachtree Corners, Georgia. This isn't just another café setting up shop; it's part of a larger scheme—expanding their sweet slice of the global market pie. Paris Baguette's Georgia Gamble...

Continue Reading
Ranger and Smith Unveil Tea-Infused Chocolate Bar

Updated Category News Views 88

Fresh Collaborations in Portland's Culinary Scene Ah, the sweet crossover in Portland's food scene is once again in the spotlight with a new entry that's sure to titillate taste buds. Ranger Chocolate Co. and Steven Smith Teamaker are at it again, rolling out a delectable creation that merges the poetic elegance of tea with the indulgent richness of chocolate. Welcome,...

Continue Reading
Intel Hit by Securities Law Suit Amid PC Market Struggles

Updated Category News Views 100

Intel Faces the Music: Legal Battles Unfold So it seems Intel's got itself in a kettle of fish. The tech giant is being dragged into a courtroom dance, courtesy of a class action lawsuit led by DJS Law Group. Shareholders who snapped up Intel shares between July 23 and October 29, 2026, might be scratching their heads, wondering if they bought into a bit of a mirage. A...

Continue Reading
NVCA Refreshes Key Venture Legal Documents for 2026

Updated Category News Views 115

Keeping Pace with Evolving Venture Norms Change never lets up in the fast-paced world of venture capital, does it? Just when you think you've got the rules figured out, the game shifts. This time, it's the National Venture Capital Association (NVCA) shaking things up. They've given a facelift to seven of their model legal documents, a move that reshapes the legal...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Natural Hydrogen: MAX Power Mining's Vision

Updated Category News Views 184

MAX Power Mining Corp. Driving Innovation in Natural Hydrogen In an era where energy demands are escalating, especially with the rise of artificial intelligence and advanced technologies, the search for sustainable power sources has reached new heights. Enter MAX Power Mining Corp. (OTC: MAXXF) (CSE: MAXX), a trailblazer in the natural hydrogen sector, demonstrating...

Continue Reading
Inland Empire Health Plan Achieves Excellence in GIS Recognition

Updated Category News Views 246

A Celebration of Achievement for Inland Empire Health Plan Inland Empire Health Plan (IEHP) has achieved remarkable recognition by winning its third Special Achievement in GIS (SAG) award from Esri, the global leader in Geographic Information System (GIS) technology. This prestigious accolade highlights IEHP's commitment to utilizing innovative technology to enhance...

Continue Reading
Ryp Labs Triumphs in Lineage’s Global Food Innovation Challenge

Updated Category News Views 226

Ryp Labs Triumphs in Lineage’s Global Food Innovation Challenge In a groundbreaking moment for sustainable food technology, Ryp Labs was announced as the standout winner of Lineage's prestigious innovation challenge aimed at transforming the global food supply chain. The challenge focused on innovative solutions that address pressing issues such as food waste and supply...

Continue Reading
Future Landscape of the UV Stabilizers Market by 2032

Updated Category News Views 176

Growth of the UV Stabilizers Market The UV stabilizers market is gaining momentum, projected to expand from USD 1.4 billion to USD 2.3 billion by 2032, with a compound annual growth rate (CAGR) of 5.5% during the 2024-2032 period. This growth is fueled by the increasing demand for materials that are durable and can endure the degrading effects of ultraviolet (UV)...

Continue Reading
Dr. Rushika Fernandopulle Joins Premera Board of Directors

Updated Category News Views 337

Dr. Rushika Fernandopulle Joins Premera's Board Premera Blue Cross is excited to announce the addition of Dr. Rushika Fernandopulle to its Board of Directors. This decision is part of a strategic effort to strengthen leadership and expertise within the organization. Dr. Fernandopulle takes over from Dr. John Jenrette, who has completed his term this year. Expertise and...

Continue Reading